PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Xencor Inc. (XNCR) on Wednesday reported a loss of $6.7 million in its fourth quarter.
The Pasadena, California-based company said it had a loss of 9 cents per share.
The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 64 cents per share.
The biotech developing antibodies for severe autoimmune/allergic diseases and cancer posted revenue of $28.2 million in the period, also exceeding Street forecasts. Six analysts surveyed by Zacks expected $21.6 million.
For the year, the company reported a loss of $91.9 million, or $1.24 per share. Revenue was reported as $125.6 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XNCR at https://www.zacks.com/ap/XNCR
/A%20SoFi%20logo%20on%20an%20office%20building%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/Stickers%20with%20AMD%20Radeon%20and%20Nvidia%20GeForce%20RTX%20graphics%20on%20new%20laptop%20computer%20by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
